Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
about
Myasthenia gravisLessons learned from more than 1,000 pancreas transplants at a single institutionA prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplantation: a single center reportVirtual high-throughput screening identifies mycophenolic acid as a novel RNA capping inhibitorA prospective, randomized trial to compare tacrolimus and prednisone with and without mycophenolate mofetil in patients undergoing renal transplantation: first report.The influence of mycophenolate mofetil and azathioprine on the same cadaveric donor renal transplantationNew immunosuppressive drugs and lung transplantation: last or least?Nonlinear relationship between enteric-coated mycophenolate sodium dose and mycophenolic acid exposure in Han kidney transplantation recipientsPharmacokinetics and pharmacodynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patients.Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetesPharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients.Mycophenolic acid counteracts B cell proliferation and plasmablast formation in patients with systemic lupus erythematosusMycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activitySafety and tolerability of the T-cell depletion protocol coupled with anakinra and etanercept for clinical islet cell transplantation.Is newer safer? Adverse events associated with first-line therapies for ANCA-associated vasculitis and lupus nephritis.A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report.Hepatic and intestinal transplantation at the University of Pittsburgh.Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy.The superiority of tacrolimus in renal transplant recipients -- the Pittsburgh experience.Long-term survival of living donor renal transplants: A single center study.The anti-fibrotic effect of mycophenolic acid-induced neutral endopeptidase.The emergence of mycophenolate mofetilin dermatology: from its roots in the world of organ transplantation to its versatile role in the dermatology treatment room.Clinically useful monoclonal antibodies in treatment.Mycophenolate mofetil: safety and efficacy in the prophylaxis of acute kidney transplantation rejection.Mycophenolic acid formulations in adult renal transplantation - update on efficacy and tolerability.Pancreas and islet cell transplantation.Mycophenolic acid response biomarkers: a cell line model system-based genome-wide screen.Karyopherins: potential biological elements involved in the delayed graft function in renal transplant recipients.Mycophenolate mofetil monotherapy in the management of paediatric uveitis.Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil.Mycophenolate mofetil in the treatment of uveitis in childrenPopulation pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil.Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling.Mycophenolic acid pharmacokinetics and related outcomes early after renal transplantInvestigation on pharmacokinetics of mycophenolic acid in Chinese adult renal transplant patientsTime-dependent clearance of mycophenolic acid in renal transplant recipientsTherapy of lupus nephritis: lessons learned from clinical research and daily care of patients.Time dependent neuroprotection of mycophenolate mofetil: effects on temporal dynamics in glial proliferation, apoptosis, and scar formation.Reassessing the Significance of Intimal Arteritis in Kidney Transplant Biopsy SpecimensUrine Metabolite Profiles Predictive of Human Kidney Allograft Status.
P2860
Q21202960-2EBF8A0A-1C48-4BDB-98AB-2D643148FF94Q24541751-C3B64CFE-6156-46A6-A6F9-113CDC0B9C1AQ28360654-07BCA8E8-FEB1-4D12-A2C1-3B7620219D37Q28477101-40323982-0072-4428-8F8E-52BB37AC8ED9Q33504334-DC2DACC4-B13F-477D-9DD6-040406136B28Q33599404-AEBB20BA-4B6B-4DEB-87D0-97703A8BAE11Q33639354-7BB9363C-D717-4CAE-8811-05318CFB4052Q33683136-ACFBBE83-81D4-4995-8CE4-6AA44E053E7DQ33684048-7D766D31-370A-43FB-80DE-6A319EB66A13Q33751549-7A4D15C1-9E26-436D-B490-0FDEE9124290Q33764989-4AE9D77B-8C18-47B4-B627-1A24F1A8D467Q33766270-7D910F7F-9267-47FC-A1DC-A8D851818849Q33781206-CEEA9993-F37A-4B1E-9C1B-2E17A9092228Q33848529-2E0C1F10-2E42-451D-8B5F-59DDDF26370DQ34124711-38ED8D72-8BB1-4976-95EA-3DFBC99D12B9Q34187619-AC2F0802-43B5-4B19-9C97-67F60775C013Q34206468-9A82C828-FE87-4E2A-9663-7BF3F3BCCD8DQ34286525-B2530D4B-A2E1-4E4F-A390-AC4E2AF10F8AQ34346715-172B6387-3DCC-4FA3-8EF7-C5A92AF75E5CQ34435197-4434F10E-8C7C-4D92-92D9-220EC25F4F70Q34457205-2AE2D4F6-D547-4409-88FF-41D936116B53Q34536203-AC8DECE9-F5C2-4103-AEB2-B282F5F4EC2AQ34543634-42305A9A-B6FB-434B-840B-3A6078C09C1DQ34607590-3CEA87BC-DE46-4C18-863B-0D620BF9091EQ34611858-A8A48970-8B53-422F-B17F-DAC60B85A731Q34701213-2C7F22B7-EEE5-44CF-8338-75A588101AD3Q35112606-A4E9F6AF-2018-4833-A8D8-D427BD0698FFQ35119530-9DD10960-187D-49C5-90A4-6AB527FB2B10Q35208743-D0E25A37-39D3-4D3A-B0D4-E585A1E7832CQ35605432-FA8BC90C-6352-4739-A175-7F701EB386A5Q35762963-C6363E98-3B51-4ACF-A045-70206B28B792Q35825497-CBB9F72D-570A-4064-94F5-6B60D7025C44Q35826755-64794E4B-2097-41EE-97ED-A8233844CC45Q35826828-2C058477-DCED-4126-AC8B-6C21268D4CF8Q35827831-FFAC1825-1979-4B78-9BDB-DE0EC7EC99EEQ36024478-B89A1C91-7356-4B57-B8B8-F80B682AB130Q36084894-AF736DD7-7228-4A9E-903B-092F07096D53Q36198340-12967439-0027-48FC-8B5C-13AE30127BA9Q36314959-26F80D74-486A-4587-A487-D3C0640E93C8Q36514964-DE467C8C-8D1D-4AEE-9F07-254931ABC6A7
P2860
Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Mycophenolate mofetil for the ...... phenolate Mofetil Study Group.
@en
Mycophenolate mofetil for the ...... phenolate Mofetil Study Group.
@nl
type
label
Mycophenolate mofetil for the ...... phenolate Mofetil Study Group.
@en
Mycophenolate mofetil for the ...... phenolate Mofetil Study Group.
@nl
prefLabel
Mycophenolate mofetil for the ...... phenolate Mofetil Study Group.
@en
Mycophenolate mofetil for the ...... phenolate Mofetil Study Group.
@nl
P1433
P1476
Mycophenolate mofetil for the ...... phenolate Mofetil Study Group.
@en
P2093
H W Sollinger
P304
P577
1995-08-01T00:00:00Z